Saturday 17 October 2026
Export REGN’s income statement to Excel — free account
Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024. In the quarter to June 2026, revenue grew 16.7%, EPS fell 4.68%, free cash flow fell 29.3% and total debt fell 26.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for three consecutive years.
790.74
5.60
−0.70%
Follow REGN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
17.90 | 17.42 | 24.43 | 17.78 | 8.26 | 14.75 | 19.38 | 16.50 | 33.92 | 45.15 |
Piotroski F-Score |
5 | 4 | 6 | 5 | 6 | 5 | 4 | 5 | 5 | 6 |
P/S ratio |
5.63 | 5.41 | 7.36 | 6.34 | 4.15 | 6.12 | 6.25 | 7.83 | 6.93 | 8.18 |
Altman Z-Score |
7.49 | 7.85 | 10.45 | 9.67 | 9.32 | 7.65 | 8.71 | 10.41 | 11.51 | 11.15 |
Altman Z″-Score (non-manufacturers) |
9.21 | 9.67 | 10.53 | 10.19 | 10.35 | 8.06 | 8.24 | 8.80 | 7.55 | 5.77 |
P/FCF ratio |
21.44 | 21.60 | 26.33 | 22.71 | 10.22 | 25.95 | 20.50 | 22.24 | 39.31 | 40.82 |
Beneish M-Score |
(2.53) | (2.25) | (2.57) | (2.70) | (1.46) | (2.07) | (2.26) | (2.17) | (2.33) | (2.77) |
P/Operating CF |
68.97 | 60.87 | 88.61 | 44.86 | 28.14 | 42.23 | 52.07 | 55.30 | 71.74 | 101.83 |
Dividend Safety Score |
77 | — | — | — | — | — | — | — | — | — |
P/B ratio |
2.58 | 2.62 | 3.72 | 3.40 | 3.56 | 4.71 | 3.70 | 4.60 | 6.62 | 8.94 |
Price to Tangible BV |
2.69 | 2.73 | 3.87 | 3.55 | 3.56 | 4.71 | 3.70 | 4.60 | 6.62 | 8.94 |
EV/Sales |
5.32 | 5.07 | 6.86 | 6.05 | 4.02 | 6.19 | 5.87 | 7.42 | 6.81 | 8.04 |
EV/EBITDA |
18.52 | 16.11 | 20.13 | 14.49 | 6.99 | 13.79 | 15.91 | 14.24 | 17.96 | 27.22 |
EV/Operating CF |
15.33 | 16.30 | 19.57 | 14.68 | 9.11 | 20.09 | 15.84 | 17.40 | 30.57 | 26.29 |
EV/FCF |
20.27 | 20.25 | 24.52 | 21.67 | 9.88 | 26.25 | 19.25 | 21.08 | 38.63 | 40.11 |
Quick Ratio |
3.28 | 3.86 | 4.82 | 4.16 | 2.98 | 2.86 | 2.86 | 3.50 | 2.98 | 2.13 |
Current Ratio |
4.13 | 4.73 | 5.69 | 5.06 | 3.56 | 3.63 | 3.67 | 4.47 | 3.82 | 2.56 |
Net Debt/EBITDA |
(1.43) | (1.41) | (1.82) | (0.99) | (0.40) | (0.23) | (1.03) | (0.78) | (0.32) | (0.48) |
Debt/Assets |
6.67% | 7.16% | 8.17% | 9.25% | 7.78% | 15.71% | 4.82% | 6.04% | 8.03% | 5.04% |
Debt/Equity |
0.09 | 0.09 | 0.10 | 0.12 | 0.11 | 0.24 | 0.06 | 0.08 | 0.11 | 0.08 |
Asset Turnover |
0.37 | 0.40 | 0.42 | 0.45 | 0.75 | 0.53 | 0.49 | 0.50 | 0.75 | 0.77 |
Operating CF/Net income |
1.11 | 1.00 | 1.16 | 1.16 | 0.88 | 0.75 | 1.15 | 0.90 | 1.09 | 1.66 |
Capex/Depreciation |
(2.23) | (1.78) | (2.20) | (4.74) | (1.93) | (2.61) | (2.04) | (2.58) | (1.87) | (4.89) |
Interest Coverage |
81.69 | 72.30 | 55.44 | 79.78 | 156.14 | 62.86 | 73.17 | 89.87 | 82.85 | 184.82 |
| 14.87% | 15.95% | 16.26% | 20.94% | 54.21% | 31.77% | 21.32% | 32.81% | 22.63% | 22.10% | |
| 11.50% | 12.46% | 12.69% | 15.88% | 37.91% | 21.98% | 15.94% | 23.85% | 15.23% | 14.23% | |
ROIC |
8.82% | 10.82% | 14.19% | 16.81% | 37.14% | 22.06% | 16.08% | 23.80% | 23.90% | 22.11% |
Return on Tangible Assets |
24.00% | 22.84% | 19.57% | 26.28% | 59.53% | 34.10% | 24.94% | 32.25% | 21.56% | 22.26% |
Average Days of Receivables |
146.10 | 159.65 | 157.70 | 159.78 | 137.09 | 176.75 | 155.05 | 159.12 | 122.72 | 121.03 |
Research and Development Expense of Revenue |
40.79% | 36.14% | 33.84% | 29.51% | 17.80% | 31.15% | 37.36% | 28.54% | 35.34% | 42.22% |
Selling, General and Administrative Expense of Revenue |
18.82% | 20.80% | 20.06% | 17.38% | 11.35% | 15.84% | 20.46% | 21.91% | 22.49% | 24.23% |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.93% | 6.92% | 6.75% | 5.96% | 3.74% | 5.08% | 7.08% | 8.31% | 8.64% | 11.52% |
Graham Net Nets |
0.11 | 0.13 | 0.13 | 0.12 | 0.11 | 0.07 | 0.10 | 0.09 | 0.04 | 0.02 |
Graham Number |
538.44 | 500.23 | 450.47 | 439.24 | 552.66 | 274.82 | 210.38 | 203.33 | 121.12 | 89.67 |
Earnings Yield |
5.59% | 5.74% | 4.09% | 5.62% | 12.11% | 6.78% | 5.16% | 6.06% | 2.95% | 2.21% |
Free Cash Flow Yield |
4.66% | 4.63% | 3.80% | 4.40% | 9.78% | 3.85% | 4.88% | 4.50% | 2.54% | 2.45% |
Revenue per Share |
137.12 | 131.62 | 122.94 | 113.66 | 152.05 | 78.97 | 60.05 | 47.69 | 55.24 | 46.42 |
Operating CF per Share |
47.60 | 40.97 | 43.06 | 46.82 | 66.99 | 24.33 | 22.25 | 20.34 | 12.30 | 14.19 |
Capex per Share |
(11.60) | (7.98) | (8.68) | (15.10) | (5.22) | (5.71) | (3.93) | (3.55) | (2.56) | (4.89) |
Free Cash Flow per Share |
36.00 | 32.98 | 34.37 | 31.73 | 61.77 | 18.62 | 18.32 | 16.79 | 9.73 | 9.30 |
Cash per Share |
82.27 | 83.53 | 101.64 | 72.29 | 53.88 | 33.34 | 29.44 | 26.04 | 13.26 | 9.92 |
Shareholders Equity per Share |
298.82 | 272.04 | 243.42 | 211.62 | 177.57 | 102.47 | 101.55 | 81.16 | 57.80 | 42.50 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
298.82 | 272.04 | 243.42 | 211.62 | 177.57 | 102.47 | 101.55 | 81.16 | 57.80 | 42.50 |
Free Cash Flow |
3,765.20 | 3,559.00 | 3,667.60 | 3,398.00 | 6,529.40 | 2,003.50 | 2,000.40 | 1,812.00 | 1,034.50 | 974.00 |
Working Capital |
13,653.50 | 14,716.60 | 16,055.80 | 12,742.80 | 10,082.40 | 7,081.70 | 5,592.50 | 5,004.80 | 3,199.50 | 1,938.69 |
Capital Expenditures |
(1,213.70) | (861.50) | (926.40) | (1,616.90) | (551.90) | (614.60) | (429.60) | (383.10) | (272.60) | (511.90) |
Net Current Asset Value |
8,720.10 | 10,255.10 | 12,372.10 | 9,333.60 | 7,348.90 | 3,641.10 | 3,973.60 | 3,470.40 | 1,714.80 | 655.97 |
EV/EBIT |
21.34 | 18.06 | 22.22 | 15.54 | 7.21 | 14.70 | 17.42 | 15.07 | 19.22 | 29.36 |
Capex to Sales |
0.08 | 0.06 | 0.07 | 0.13 | 0.03 | 0.07 | 0.07 | 0.07 | 0.05 | 0.11 |
Price to Operating Income |
22.57 | 19.26 | 23.86 | 16.28 | 7.46 | 14.53 | 18.55 | 15.90 | 19.56 | 29.87 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.11 | 0.11 | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.06 | 0.06 | 0.05 |
Cash ROIC |
8.85% | 8.67% | 9.28% | 10.26% | 24.69% | 11.58% | 13.32% | 14.76% | 12.53% | 16.68% |
Accounts Receivable Turnover |
2.40 | 2.39 | 2.39 | 2.14 | 3.17 | 2.46 | 2.61 | 2.44 | 3.28 | 3.16 |
Accounts Payable Turnover |
2.43 | 2.82 | 3.04 | 2.71 | 4.69 | 2.51 | 2.40 | 2.11 | 0.75 | 0.39 |
Inventory Turnover |
0.67 | 0.70 | 0.73 | 0.72 | 1.26 | 0.67 | 0.60 | 0.44 | 0.71 | 0.94 |
Average Days of Payables |
163.15 | 146.24 | 121.93 | 137.82 | 84.46 | 154.98 | 199.46 | 190.76 | 163.80 | 1,070.64 |
Days of Inventory on Hand |
556.14 | 571.87 | 518.71 | 561.84 | 292.19 | 624.66 | 675.28 | 1,006.44 | 667.40 | 486.37 |
Average Receivables |
5,976.50 | 5,939.60 | 5,498.00 | 5,682.60 | 5,075.60 | 3,450.15 | 2,514.40 | 2,108.75 | 1,792.96 | 1,539.71 |
Average Payables |
864.25 | 698.05 | 597.90 | 576.60 | 519.75 | 446.80 | 318.15 | 198.20 | 528.65 | 761.60 |
Average Inventory |
3,144.05 | 2,833.90 | 2,491.20 | 2,176.60 | 1,933.95 | 1,666.05 | 1,283.35 | 938.65 | 562.73 | 318.97 |
Average Assets |
39,159.05 | 35,419.80 | 31,147.35 | 27,324.65 | 21,299.05 | 15,984.25 | 13,269.85 | 10,249.40 | 7,868.88 | 6,291.30 |
Average Common Equity |
30,305.25 | 27,663.35 | 24,318.55 | 20,716.40 | 14,897.05 | 11,057.50 | 9,923.50 | 7,450.70 | 5,296.67 | 4,052.04 |
Columns are period end dates